Sierra Oncology Stock Price and Value Analysis

Should you buy Sierra Oncology stock? (NasdaqGM:SRRA). Let's see how it does in our automated value investing analysis system.

  • This company has stable growth.
  • This stock looks overpriced.
  • This company is not making money.
  • This company is less known than others.
  • This company pays no dividend.

Inside the SRRA Numbers

SRRA Price
(Sierra Oncology stock price per share)
[?] PE Ratio versus Sector 100% lower than other Healthcare stocks
[?] PE Ratio versus Industry 100% lower than other Biotechnology stocks
[?] Free Cash Flow Jitter 21%

This stock has short interest! This means that people have shorted it.

Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.

As of the latest analysis, there are 25,899 shares shorted. With 3,278,956 shares available for purchase and an average trading volume over the past 10 trading days of 68,590, it would take at least 0.378 days for all of the short holders to cover their shorts.

Is Sierra Oncology Stock on Sale?

Based on our analysis, we believe that you should not buy Sierra Oncology right now. It might be a good stock to own—we just can't prove it with value analysis right now. Proceed with caution.

Should You Buy SRRA Stock?

Does Sierra Oncology have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.